Halozyme Therapeutics, Inc. vs. Novavax Inc
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| HALO | NVAX | |
|---|---|---|
| Market Cap | $12.53 billion | $2.10 billion |
HALO leads on 1 of 1 size & scale factors.
Dividend
| HALO | NVAX | |
|---|---|---|
| Dividend Yield | — | 10.00% |
HALO and NVAX split the dividend factors evenly.
Risk & Sentiment
| HALO | NVAX | |
|---|---|---|
| Short Interest | 9.79% | 25.98% |
HALO leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, NVAX overview, NVAX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.